82 search results for: symposium

.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

ADVENT at EAACI 2025
Congress
13
June
2025
Congress
ADVENT at EAACI 2025

Join Profs. Brian Lipworth, Zuzana Diamant, and Philippe Gevaert at an sponsored symposium about the latest strategies for the management of co-existing type 2 asthma and severe and/or uncontrolled CRSwNP.

ADVENT at ERS-ISIAN 2025
Congress
20
June
2025
Congress
ADVENT at ERS-ISIAN 2025

Join experts Vibeke Backer, MD, DMSC, and Sietze Reitsma, MD, at an educational symposium involving a comprehensive exploration of the type 2 inflammation and its pivotal role in the pathogenesis and management of CRSwNP.

ADVENT at NAPNAP 2025
Congress
12
March
2025
Congress
ADVENT at NAPNAP 2025

Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma
Type 2 Inflammation
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma
expert video

Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function

View more
Pediatric Asthma Trajectory and Clinical Remission
Type 2 Inflammation
Pediatric Asthma Trajectory and Clinical Remission
expert video

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.

View more
Multifaceted Role of IL-13 in Airway Remodeling
Type 2 Inflammation
Multifaceted Role of IL-13 in Airway Remodeling
expert video

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.

View more
Mucus Plugging as a Potential Target in Asthma Management
Type 2 Inflammation
Mucus Plugging as a Potential Target in Asthma Management
expert video

Join Dr. Celeste Porsbjerg as she explores the mechanisms underlying mucus plugging development as mucociliary clearance. She explains how type 2 cytokines—particularly IL-13—impair this clearance mechanism, leading to mucus plugging, and worsened asthma outcomes.

View more
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
Congress
11
March
2024
Congress
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

World Congress on Itch (WCI) 2023 | Miami
Congress
7
November
2023
Congress
World Congress on Itch (WCI) 2023 | Miami

Exploration of the shared mechanisms of itch across AD, PN, and CSU as well as the distinct ways itch manifests in each disease.

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
On Demand
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU

Drs. Elmariah, Kim, and Metz explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

GUF PNG
Congress
4
December
2024
Congress
Translating the Science of CSU: From Pathogenesis to Patient Outcomes

Join Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau as they discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, treatment challenges, and emerging therapies.